Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 214-220 , May 2007

The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer

  • Jesco Pfitzenmaier, M.D.

      Affiliations

    • Department of Urology, Medical School, University of Washington, Seattle, WA 98195-6510, USA
    • Department of Urology, Medical School, University of Heidelberg, Heidelberg, Germany
    • ,
  • William J. Ellis, M.D.

      Affiliations

    • Department of Urology, Medical School, University of Washington, Seattle, WA 98195-6510, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-206-543-3640; fax: +1-206-543-3272.
    • ,
  • Sarah Hawley, M.S.

      Affiliations

    • Public Health Division (Statistics), Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    • ,
  • Edward W. Arfman, B.A.

      Affiliations

    • Puget Sound VA Medical Center, Seattle, WA 98108-1597, USA
    • ,
  • Jeffrey R. Klein, B.S.

      Affiliations

    • Department of Urology, Medical School, University of Washington, Seattle, WA 98195-6510, USA
    • ,
  • Paul H. Lange, M.D.

      Affiliations

    • Department of Urology, Medical School, University of Washington, Seattle, WA 98195-6510, USA
    • ,
  • Robert L. Vessella, Ph.D.

      Affiliations

    • Department of Urology, Medical School, University of Washington, Seattle, WA 98195-6510, USA
    • Puget Sound VA Medical Center, Seattle, WA 98108-1597, USA

Received 24 January 2006 ,Revised 6 September 2006 ,Accepted 7 September 2006.

References 

  1. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol. 2000;164:101–105
  2. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416–419
  3. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528–534
  4. Dejter SW, Martin JS, McPherson RA, et al. Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: A comparative evaluation. Urology. 1988;32:288–292
  5. Kasahara K, Taguchi T, Yamasaki I, et al. Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy. Int J Oncol. 2001;19:543–549
  6. Takahashi S, Alcaraz A, Brown JA, et al. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Clin Cancer Res. 1996;2:137–145
  7. Alcaraz A, Takahashi S, Brown JA, et al. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 1994;54:3998–4002
  8. Lerner SE, Blute ML, Bergstralh EJ, et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996;156:137–143
  9. Cote RJ, Rosen PP, Lesser ML, et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol. 1991;9:1749–1756
  10. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88:1652–1658
  11. Moreno J, Croce C, Fischer R, et al. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res. 1992;52:6110–6112
  12. Katz A, Olsson C, Raffo A, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 1994;43:765–775
  13. Cama C, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer. II (A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen). J Urol. 1995;153:1373–1378
  14. Melchior SW, Corey E, Ellis WJ, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res. 1997;3:249–256
  15. Wood DP, Banks ER, Humphreys S, et al. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer. 1994;74:2533–2540
  16. Oefelein MG, Kaul K, Herz B, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol. 1996;155:238–242
  17. Israeli RS, Miller WH, Su SL, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostate tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 1994;54:6306–6310
  18. Ellis WJ, Pfitzenmaier J, Colli J, et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology. 2003;61:277–281
  19. Corey E, Arfman EW, Liu AY, et al. Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem. 1997;43:443–452
  20. Klein CA, Seidl S, Petat-Dutter K, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 2002;20:387–392
  21. Riesenberg R, Oberneder R, Kriegmair M, et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry. 1993;99:61–66
  22. Mueller P, Carroll P, Bowers E, et al. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer. 1998;83:538–546
  23. Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001;7:4080–4085
  24. Rouzier R, Bourstyn E, Grozier F, et al. Immunocytochemical detection of bone marrow micrometastases in colorectal carcinoma patients, using a monoclonal antibody to villin. Cytometry. 2001;46:281–289
  25. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  26. Hosch SB, Braun S, Pantel K. Characterization of disseminated tumor cells. Semin Surg Oncol. 2001;20:265–271
  27. Weckermann D, Wawroschek F, Krawczak G, et al. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?. Urol Res. 1999;27:285–290
  28. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865–873
  29. Cameron MD, Schmidt EE, Kerkvliet N, et al. Temporal progression of metastasis in lung: Cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60:2541–2546
  30. Naumov GN, MacDonald IC, Chambers AF, et al. Solitary cancer cells as a possible source of tumour dormancy?. Semin Cancer Biol. 2001;11:271–276
  31. Brenner H, Hakulinen T. Are patients diagnosed with breast cancer before age 50 years ever cured?. J Clin Oncol. 2004;22:432–438
  32. Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002;8:2073–2084
  33. Latza U, Niedobitek G, Schwarting R, et al. Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol. 1990;43:213–219

☆ This work was supported by the NIDDK O’Brien Center Award, Richard M. Lucas Foundation, Department of Veteran’s Affairs, NIH SPORE Grant, and Deutsche Forschungsgemeinschaft (DFG).

PII: S1078-1439(06)00292-4

doi: 10.1016/j.urolonc.2006.09.018

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 214-220 , May 2007

Article Tools

* Image Usage & Resolution